Delta Tocotrienol and Bevacizumab for Recurrent Ovarian Cancer

Female doctor looking at patient scans on hologram screen.
Check out Dr. Kirsten West’s write up on a clinical trial to assess if the combination of delta tocotrienol and bevacizumab delays the progression of multiresistant ovarian cancer. Learn how the results show that multiple therapeutic actions and the low toxicity of delta tocotrienol demonstrate synergistic effects with bevacizumab in ovarian cancer. Click here to read in its entirety: